Vivek Ramaswamy ramps up biotech startup #14 — this time working on a gene therapy for sickle cell disease and β-thalassemia
Vivek Ramaswamy?s Roivant Sciences has nabbed its latest clinical-stage program for biotech startup #14 ? Aruvant ? and this time they?re going up against a couple of the leaders in the gene therapy world. Their new drug is now dubbed RVT-1801, and it has a familiar profile, inserting a modified
- Vivek Ramaswamy’s Roivant Sciences has nabbed its latest clinical-stage program for biotech startup #14 — Aruvant — and this time they’re going up against a couple of the leaders in the gene therapy world.
- Their new drug is now dubbed RVT-1801, and it has a familiar profile, inserting a modified fetal hemoglobin gene into autologous stem cells through a lentiviral vehicle in order to treat sickle cell disease and β-thalassemia.
- The drug is coming from the lab of Punam Malik, director of the Cincinnati Comprehensive Sickle Cell Center at Cincinnati Children’s, which received an undisclosed upfront payment and a milestone schedule.
- Roivant is also establishing a non-profit group to improve access to drugs for patients in the developing world.